Patents by Inventor Rosy Donn

Rosy Donn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND METHODS FOR TREATING OCULAR VASCULOPATHIES
    Publication number: 20080118548
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.
    Type: Application
    Filed: January 31, 2008
    Publication date: May 22, 2008
    Applicant: ALLERGAN, INC.
    Inventors: Glenn HUANG, Brittany Jackson, James Burke, Ton Lin, Patrick Hughes, Larry Wheeler, Rosy Donn
  • SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND METHODS FOR TREATING OCULAR VASCULOPATHIES
    Publication number: 20080118549
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.
    Type: Application
    Filed: January 31, 2008
    Publication date: May 22, 2008
    Applicant: ALLERGAN, INC.
    Inventors: Glenn HUANG, Brittany Jackson, James Burke, Ton Lin, Patrick Hughes, Larry Wheeler, Rosy Donn
  • SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND METHODS FOR TREATING OCULAR VASCULOPATHIES
    Publication number: 20080118547
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.
    Type: Application
    Filed: January 31, 2008
    Publication date: May 22, 2008
    Applicant: ALLERGAN, INC.
    Inventors: Glenn Huang, Brittany Jackson, James Burke, Ton Lin, Patrick Hughes, Larry Wheeler, Rosy Donn
  • Sustained release intraocular implants and methods for preventing retinal dysfunction
    Publication number: 20050244506
    Abstract: Biocompatible intraocular microspheres and implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or to prevent the occurrence of one or more ocular conditions, to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like, to enhance normal retinal function and/or to lower intraocular pressure.
    Type: Application
    Filed: April 29, 2005
    Publication date: November 3, 2005
    Applicant: ALLERGAN, INC.
    Inventors: James Burke, Patrick Hughes, Werhner Orilla, Ton Lin, Maria Escobar, Glenn Huang, Kai-Ming Zhang, Larry Wheeler, Rosy Donn
  • Sustained release intraocular implants and methods for treating ocular vasculopathies
    Publication number: 20050244463
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.
    Type: Application
    Filed: April 30, 2004
    Publication date: November 3, 2005
    Applicant: Allergan, Inc.
    Inventors: Glenn Huang, Brittany Jackson, James Burke, Ton Lin, Patrick Hughes, Larry Wheeler, Rosy Donn
  • Sustained release intraocular implants and methods for preventing retinal dysfunction
    Publication number: 20050244479
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to prevent the occurrence of one or more ocular conditions, or to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like.
    Type: Application
    Filed: April 30, 2004
    Publication date: November 3, 2005
    Applicant: Allergan, Inc.
    Inventors: Glenn Huang, James Burke, Patrick Hughes, Kai-Ming Zhang, Ton Lin, Larry Wheeler, Rosy Donn
  • Intraocular implants and methods for improving vision
    Publication number: 20050244476
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others or to improve vision in a normal eye.
    Type: Application
    Filed: April 29, 2005
    Publication date: November 3, 2005
    Applicant: ALLERGAN, INC.
    Inventors: James Burke, Patrick Hughes, Kai-Ming Zhang, Ton Lin, Glenn Huang, Brittany Jackson, Larry Wheeler, Rosy Donn